multicancer platform
Signal-X
We are developing Signal-X, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity.
.jpg)
We are developing blood tests that detect cancer in its earliest stages so we can transform cancer into a disease that’s preventable and curable.
For our first test, Signal-C™, we identify the regions associated with colorectal cancer, including pre-cancerous adenomas, allowing us to detect the disease in its earliest stages – in many cases, before it progresses to cancer.
Starting from a deep knowledge of the disease, we have built a technological platform able to “read” the signal of cancer in blood.
We are developing Signal-X, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity.
Our first blood test, Signal-C, accurately detects colorectal cancer with a sensitivity of 92% and specificity of 97% (abstract presented at ASCO 2021).
Signal-C is also focused on detecting Advanced Adenoma; our first experiments show a sensitivity of 52% and a specificity of 90 (abstract presented at EACR 2021).
We are applying our multi-omics + computational biology + machine learning approach to capture cancer’s signal for high-burden gastrointestinal cancers, including pancreatic (“Signal-P”), liver (“Signal-L”), and gastric/stomach (“Signal-G”).
We presented proof of concept studies for various cancers with high accuracy, including for early stages (abstract presented at ESMO 2020)
We are driven forward by a vision of a future where cancer is curable.
Press releases
New Data from Universal DX Demonstrates Effective Detection of Early-stage Colorectal Cancer Using Combination of Methylation, Fragmentation and Machine Learning
Jan 20, 2023
Press releases
New Data from Universal DX Demonstrates Effective Detection of Early-stage Colorectal Cancer Using Combination of Methylation, Fragmentation and Machine Learning
Jan 20, 2023
Press releases
New Data from Universal DX Demonstrates Effective Detection of Early-stage Colorectal Cancer Using Combination of Methylation, Fragmentation and Machine Learning
Jan 20, 2023
Press releases
Universal DX Presents Methylation Biomarker Data at AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer
Nov 17, 2022
Press releases
Universal DX Presents Methylation Biomarker Data at AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer
Nov 17, 2022
Press releases
Universal DX Presents Methylation Biomarker Data at AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer
Nov 17, 2022
Press releases
New Findings from Universal DX: Through a Simple Blood Test, Our Body’s Gut Bacteria Can Help Detect Early-stage Colorectal Cancer
Sep 12, 2022
Press releases
New Findings from Universal DX: Through a Simple Blood Test, Our Body’s Gut Bacteria Can Help Detect Early-stage Colorectal Cancer
Sep 12, 2022
Press releases
New Findings from Universal DX: Through a Simple Blood Test, Our Body’s Gut Bacteria Can Help Detect Early-stage Colorectal Cancer
Sep 12, 2022